Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGD | P52209 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4449219 | 1.00 | PGD (0.37) | PGDLMNAALDH1A1OR51E2TDP1 | |
| SCHEMBL6686437 | 1.00 | PGD (0.37) | PGDLMNAALDH1A1OR51E2TDP1 | |
| SCHEMBL18902784 | 1.00 | PGD (0.37) | PGDLMNAALDH1A1OR51E2TDP1 | |
| SCHEMBL4445885 | 0.96 | PGD (0.36) | PGDLMNAALDH1A1OR51E2TDP1 | |
| SCHEMBL1000048 | 0.92 | PGD (0.37) | PGDLMNAALDH1A1OR51E2TDP1 | |
| SCHEMBL5063165 | 0.87 | TSHR (0.50) | PGDLMNAALDH1A1TSHRHIF1A | |
| SCHEMBL31134456 | 0.87 | TSHR (0.50) | PGDLMNAALDH1A1TSHRHIF1A | |
| SCHEMBL31482274 | 0.87 | TSHR (0.50) | PGDLMNAALDH1A1TSHRHIF1A | |
| SCHEMBL22388686 | 0.87 | TSHR (0.50) | PGDLMNAALDH1A1TSHRHIF1A | |
| SCHEMBL31028137 | 0.87 | TSHR (0.50) | PGDLMNAALDH1A1TSHRHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220259-A1 | Topical treatment of dermatological disorders associated with reactive or dilated blood vessels | YU RUEY J (US) | 2004-11-04 | — | — | US | claimed |
| WO-2004093722-A2 | TOPICAL TREATMENT OF DERMATOLOGICAL DISORDERS ASSOCIATED WITH REACTIVE OR DILATED BLOOD VESSELS | YU RUEY J (US) | 2004-11-04 | — | — | WO | claimed |
| WO-2015157213-A1 | EGFR-TARGETED NANOPARTICLES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-10-15 | — | — | WO | disclosed |
| WO-2014133549-A1 | NANOPARTICLES STABILIZED WITH NITROPHENYLBORONIC ACID COMPOSITIONS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-09-04 | — | — | WO | disclosed |
| WO-2011006011-A2 | THERANOSTIC POLYCATION BEACONS COMPRISING OLIGOETHYLENEAMINE REPEATING UNITS AND LANTHANIDE CHELATES | VIRGINIA TECH INTELLECTUAL PROPERTIES INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| US-20110009478-A1 | THERANOSTIC POLYCATION BEACONS COMPRISING OLIGOETHYLENEAMINE REPEATING UNITS AND LANTHANIDE CHELATES | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. | 2011-01-13 | — | — | US | disclosed |
| US-20040220259-A1 | Topical treatment of dermatological disorders associated with reactive or dilated blood vessels | YU RUEY J (US) | 2004-11-04 | — | — | US | disclosed |
| WO-2004093722-A2 | TOPICAL TREATMENT OF DERMATOLOGICAL DISORDERS ASSOCIATED WITH REACTIVE OR DILATED BLOOD VESSELS | YU RUEY J (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220259-A1 | Topical treatment of dermatological disorders associated with reactive or dilated blood vessels | AKR1C3, ALDOA, AKR1C2 | PGD 13/4885LMNA 1780/4885ALDH1A1 83/4885 |
| US-20110009478-A1 | THERANOSTIC POLYCATION BEACONS COMPRISING OLIGOETHYLENEAMINE REPEATING UNITS AND LANTHANIDE CHELATES | TRDMT1, LGALS3, ELAVL1 | PGD 705/4885LMNA 415/4885ALDH1A1 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.